GAITHERSBURG, Md, (Reuters) – GlaxoSmithKline Plc’s diabetes drug Avandia should be allowed to stay on the market but with additional warnings, U.S. health advisers recommended yesterday, easing a threat of further costly litigation that could have followed a ban.
A majority of the 33-member panel of outside experts found data raised concerns about heart attacks associated with the widely used pill, but not enough to warrant its withdrawal from the market.
The Food and Drug Administration will make the final decision in the coming months and the agency usually follows recommendations from its advisory committees.
